A Phase 1 interventional study of Atorvastatin and Atorvastatin in Pediatric Heterozygous Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 3 sites in 3 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-03-15.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 64th largest by enrollment of the 75 interventional ones that give a count, is one of 13 that started in 2008, is one of 4 in phase 1, and was the 30th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 13 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 75 interventional studies. Of the 69 that completed or were terminated, 33 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 77 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
19 studies in Hypercholesterolemia by Viatris Inc.: none open now, none under way, none of them phase 3. Of 19 finished, 10 (53%) have results posted.
Among the 19 studies in Hypercholesterolemia by Viatris Inc., this one is the 15th largest by enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2008, is one of 3 in phase 1, and was the 9th registered.
Viatris Inc.’s Hypercholesterolemia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, from their registry updates:
Among Viatris Inc.’s 19 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate pharmacokinetics, pharmacodynamics, safety and tolerability of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6-10 years will be administered with atorvastatin tablet formulation with initial doses based on age cohort.
Drug: Atorvastatin
10-17 years will be administered 10-mg daily dose of atorvastatin tablet formulation.
Drug: Atorvastatin
6-10 years Tanner Stage 1 will be administered 5-mg daily dose of an atorvastatin pediatric tablet formulation. Dose may be doubled if subjects have not attained target LDL (\<3.35 mmol/L) after 4-week treatment.
10-17 years Tanner Stage 2 will be administered 10-mg daily dose of atorvastatin tablet formulation. Dose may be doubled if subjects have not attained target LDL (\<3.35 mmol/L) after 4-week treatment.
Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Atorvastatin Apparent Clearance (CL/F)
Parent-metabolite population PK model built using sparse blood samples from both Tanner Stage 1 and Tanner Stage 2+. Blood sampling times: Weeks 2 and 6: single sample between 4 and 12 hours postdose; Weeks 4 and 8: predose, 1 hour, and 2 hours postdose. Plasma samples were analyzed for atorvastatin and active hydroxyacid metabolite (o-hydroxyatorvastatin) concentrations using a validated, sensitive, and specific high-performance liquid chromatography tandem mass spectrometric method. Data presented are the result of the model used.
Time frame: Week 2, Week 4, Week 6, Week 8
Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Apparent Volume of Distribution of the Central Compartment (Vc/F)
Parent-metabolite population PK model built using sparse blood samples from Tanner Stages 1 and 2+. Sampling times: Weeks 2 + 6: single sample between 4 -12 hours postdose; Weeks 4 + 8: predose, 1 + 2 hours postdose. Plasma samples analyzed for atorvastatin and active hydroxyacid metabolite (o-hydroxyatorvastatin) concentrations using validated, sensitive, specific high-performance liquid chromatography tandem mass spectrometric method. Vc/F value based on 70 kg body weight. Parameter estimation uncertainty (95% CI) by non-parametric bootstrap analysis. Data presented are result of model used.
Time frame: Week 2, Week 4, Week 6, Week 8
Absolute Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)
Low-density lipoprotein cholesterol (LDL-C) measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8
Percent Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)
Low-density Lipoprotein Cholesterol (LDL-C): percent (%) change from baseline by treatment over time = \[LDL-C at observation minus LDL-C at Week 0\] divided by LDL-C at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8
Absolute Change From Baseline in Total Cholesterol (TC)
Total Cholesterol measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8
Percent Change From Baseline in Total Cholesterol (TC)
Total cholesterol (TC): percent (%) change from baseline by treatment over time = \[TC at observation minus TC at Week 0\] divided by TC at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8
Absolute Change From Baseline in Triglycerides (TG)
Change from baseline in triglycerides measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8
Percent Change From Baseline in Triglycerides (TG)
Triglycerides (TG): percent (%) change from baseline by treatment over time = \[TG at observation minus TG at Week 0\] divided by TG at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8
Absolute Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)
Change from baseline in high-density lipoprotein cholesterol measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)
High-density lipoprotein cholesterol (HDL-C): percent (%) change by treatment over time = \[HDL-C at observation minus HDL-C at Week 0\] divided by HDL-C at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8
Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1)
Change from baseline in Apolipoprotein A-1 measured in grams per liter (g/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1)
Apolipoprotein A-1 (Apo A-1): percent (%) change from baseline by treatment over time = \[Apo A-1 at observation minus Apo A-1 at Week 0\] divided by Apo A-1 at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8
Absolute Change From Baseline in Apolipoprotein B (Apo B)
Change from baseline in Apolipoprotein B measured in grams per liter (g/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8
Percent Change From Baseline in Apolipoprotein B (Apo B)
Apolipoprotein B (Apo B): percent (%) change from baseline by treatment over time = \[Apo B at observation minus Apo B at Week 0\] divided by Apo B at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8
Absolute Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C)
Change from baseline in very low-density lipoprotein-cholesterol (VLDL-C) measured in millimoles per liter (mmol/L). Change from baseline = value at observation minus baseline value. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8
Percent Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C)
Very low-density lipoprotein-cholesterol (VLDL-C): percent (%) change from baseline by treatment over time = \[VLDL-C at observation minus VLDL-C at Week 0\] divided by VLDL-C at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8
Absolute Change From Baseline in Flow-Mediated Dilatation at Week 8
Brachial artery flow-mediated dilatation (FMD) = (max minus baseline diameter divided by baseline diameter) x 100%. Standardized image acquisition: brachial artery images recorded for one minute at rest, blood pressure cuff inflated to 250 mm Hg for 5 minutes with brachial artery imaged continuously throughout cuff inflation, cuff released to produce reactive hyperaemia and the brachial artery imaged continuously for 3 minutes after release. Total duration of measurement approximately 25 minutes. Change from baseline = value at observation minus baseline value.
Time frame: Baseline, Week 8
Percent Change From Baseline in Flow-Mediated Dilatation at Week 8
Brachial Flow-Mediated Dilatation (FMD) = (max minus baseline diameter divided by baseline diameter) x 100%. .
Time frame: Baseline, Week 8
Subjects were enrolled at 3 medical centers and participated in the study between 02 December 2008 and 13 May 2009.
| Milestone | Atorvastatin (5 mg, 10 mg): Tanner Stage 1 | Atorvastatin (10 mg, 20 mg): Tanner Stage 2+ |
|---|---|---|
| Started | 15 | 24 |
| Completed | 15 | 24 |
| Not completed | 0 | 0 |
Parent-metabolite population PK model built using sparse blood samples from both Tanner Stage 1 and Tanner Stage 2+. Blood sampling times: Weeks 2 and 6: single sample between 4 and 12 hours postdose; Weeks 4 and 8: predose, 1 hour, and 2 hours postdose. Plasma samples were analyzed for atorvastatin and active hydroxyacid metabolite (o-hydroxyatorvastatin) concentrations using a validated, sensitive, and specific high-performance liquid chromatography tandem mass spectrometric method. Data presented are the result of the model used.
| L/hr | Atorvastatin (5 mg, 10 mg): Tanner Stage 1 | Atorvastatin (10 mg, 20 mg): Tanner Stage 2+ |
|---|---|---|
| Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Atorvastatin Apparent Clearance (CL/F) | 553 | 543 |
Low-density lipoprotein cholesterol (LDL-C) measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.
| mmol/L | Stayed at 5 mg: Tanner Stage 1 | Titrated to 10 mg: Tanner Stage 1 | Stayed at 10 mg: Tanner Stage 2+ | Titrated to 20 mg: Tanner Stage 2+ |
|---|---|---|---|---|
| Baseline | 4.87 ± 0.48 | 6.37 ± 1.10 | 5.11 ± 0.65 | 6.23 ± 1.00 |
| Week 2 | -1.75 ± 0.72 | -1.62 ± 0.46 | -1.95 ± 0.52 | -1.90 ± 0.72 |
| Week 4 | -2.07 ± 0.50 | -1.94 ± 0.56 | -2.24 ± 0.57 | -2.27 ± 1.04 |
| Week 6 | -1.89 ± 0.42 | -2.57 ± 0.70 | -2.12 ± 0.74 | -2.55 ± 1.02 |
| Week 8 | -1.80 ± 0.63 | -2.71 ± 0.60 | -1.99 ± 0.58 | -2.60 ± 1.01 |
Low-density Lipoprotein Cholesterol (LDL-C): percent (%) change from baseline by treatment over time = \[LDL-C at observation minus LDL-C at Week 0\] divided by LDL-C at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).
| percent change in LDL-C | Stayed at 5 mg: Tanner Stage 1 | Titrated to 10 mg: Tanner Stage 1 | Stayed at 10 mg: Tanner Stage 2+ | Titrated to 20 mg: Tanner Stage 2+ |
|---|---|---|---|---|
| Week 2 | -36.27 ± 14.72 | -25.70 ± 7.76 | -38.14 ± 9.35 | -30.27 ± 9.22 |
| Week 4 | -42.33 ± 8.24 | -30.27 ± 5.72 | -43.66 ± 7.78 | -35.13 ± 12.01 |
| Week 6 | -38.87 ± 7.84 | -40.01 ± 6.34 | -41.22 ± 11.34 | -39.73 ± 10.40 |
| Week 8 | -36.78 ± 11.16 | -42.70 ± 6.45 | -38.45 ± 7.84 | -40.39 ± 11.71 |
Total Cholesterol measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.
| mmol/L | Stayed at 5 mg: Tanner Stage 1 | Titrated to 10 mg: Tanner Stage 1 | Stayed at 10 mg: Tanner Stage 2+ | Titrated to 20 mg: Tanner Stage 2+ |
|---|---|---|---|---|
| Baseline | 6.76 ± 0.46 | 8.58 ± 1.06 | 6.92 ± 0.71 | 8.40 ± 1.10 |
| Week 2 | -1.89 ± 0.79 | -2.04 ± 0.69 | -2.11 ± 0.53 | -2.28 ± 0.82 |
| Week 4 | -2.27 ± 0.63 | -2.24 ± 0.49 | -2.37 ± 0.61 | -2.66 ± 1.29 |
| Week 6 | -2.03 ± 0.53 | -2.86 ± 0.79 | -2.28 ± 0.73 | -2.95 ± 1.19 |
| Week 8 | -1.89 ± 0.44 | -3.20 ± 0.65 | -2.26 ± 0.69 | -3.22 ± 1.14 |
Total cholesterol (TC): percent (%) change from baseline by treatment over time = \[TC at observation minus TC at Week 0\] divided by TC at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).
| percent change in TC | Stayed at 5 mg: Tanner Stage 1 | Titrated to 10 mg: Tanner Stage 1 | Stayed at 10 mg: Tanner Stage 2+ | Titrated to 20 mg: Tanner Stage 2+ |
|---|---|---|---|---|
| Week 2 | -28.06 ± 11.23 | -24.11 ± 8.97 | -30.60 ± 7.49 | -26.78 ± 7.59 |
| Week 4 | -33.37 ± 7.81 | -26.12 ± 4.24 | -33.98 ± 7.13 | -30.54 ± 11.60 |
| Week 6 | -29.99 ± 8.00 | -33.12 ± 6.83 | -32.80 ± 8.97 | -34.06 ± 9.94 |
| Week 8 | -27.80 ± 5.56 | -37.17 ± 5.28 | -32.43 ± 8.53 | -37.45 ± 9.89 |
Change from baseline in triglycerides measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.
| mmol/L | Stayed at 5 mg: Tanner Stage 1 | Titrated to 10 mg: Tanner Stage 1 | Stayed at 10 mg: Tanner Stage 2+ | Titrated to 20 mg: Tanner Stage 2+ |
|---|---|---|---|---|
| Baseline | 0.76 ± 0.15 | 0.95 ± 0.27 | 1.03 ± 0.37 | 1.20 ± 0.50 |
| Week 2 | 0.05 ± 0.34 | -0.08 ± 0.28 | 0.05 ± 0.68 | 0.00 ± 0.47 |
| Week 4 | -0.05 ± 0.29 | -0.26 ± 0.30 | -0.10 ± 0.51 | -0.10 ± 0.37 |
| Week 6 | 0.40 ± 0.62 | -0.04 ± 0.24 | -0.12 ± 0.42 | -0.04 ± 0.32 |
| Week 8 | 0.02 ± 0.28 | -0.16 ± 0.37 | -0.31 ± 0.43 | -0.28 ± 0.41 |
Triglycerides (TG): percent (%) change from baseline by treatment over time = \[TG at observation minus TG at Week 0\] divided by TG at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).
| percent change in TG | Stayed at 5 mg: Tanner Stage 1 | Titrated to 10 mg: Tanner Stage 1 | Stayed at 10 mg: Tanner Stage 2+ | Titrated to 20 mg: Tanner Stage 2+ |
|---|---|---|---|---|
| Week 2 | 5.66 ± 38.26 | -6.87 ± 29.08 | 28.37 ± 85.32 | -0.56 ± 32.19 |
| Week 4 | -6.20 ± 32.55 | -21.43 ± 30.42 | 1.27 ± 50.81 | -7.60 ± 25.75 |
| Week 6 | 57.06 ± 78.73 | -1.27 ± 23.91 | -4.43 ± 32.52 | -2.72 ± 24.80 |
| Week 8 | 1.69 ± 31.48 | -9.88 ± 33.31 | -20.94 ± 39.24 | -21.11 ± 23.85 |
Change from baseline in high-density lipoprotein cholesterol measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.
| mmol/L | Stayed at 5 mg: Tanner Stage 1 | Titrated to 10 mg: Tanner Stage 1 | Stayed at 10 mg: Tanner Stage 2+ | Titrated to 20 mg: Tanner Stage 2+ |
|---|---|---|---|---|
| Baseline | 1.35 ± 0.12 | 1.45 ± 0.29 | 1.17 ± 0.18 | 1.18 ± 0.23 |
| Week 2 | 0.08 ± 0.24 | -0.10 ± 0.29 | -0.05 ± 0.26 | -0.01 ± 0.20 |
| Week 4 | -0.02 ± 0.05 | 0.00 ± 0.19 | 0.02 ± 0.21 | -0.01 ± 0.28 |
| Week 6 | -0.12 ± 0.29 | -0.01 ± 0.18 | 0.04 ± 0.14 | -0.03 ± 0.23 |
| Week 8 | 0.04 ± 0.22 | -0.07 ± 0.21 | 0.08 ± 0.25 | -0.08 ± 0.22 |
High-density lipoprotein cholesterol (HDL-C): percent (%) change by treatment over time = \[HDL-C at observation minus HDL-C at Week 0\] divided by HDL-C at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).
| percent change in HDL-C | Stayed at 5 mg: Tanner Stage 1 | Titrated to 10 mg: Tanner Stage 1 | Stayed at 10 mg: Tanner Stage 2+ | Titrated to 20 mg: Tanner Stage 2+ |
|---|---|---|---|---|
| Week 2 | 5.38 ± 17.32 | -6.45 ± 21.01 | -4.11 ± 19.96 | -0.77 ± 17.66 |
| Week 4 | -1.99 ± 3.90 | 1.59 ± 13.18 | 1.04 ± 17.38 | 1.77 ± 23.22 |
| Week 6 | -10.18 ± 22.70 | -0.64 ± 10.35 | 3.28 ± 11.63 | -2.78 ± 21.49 |
| Week 8 | 2.50 ± 15.02 | -2.84 ± 14.49 | 5.99 ± 21.02 | -5.19 ± 17.76 |
Change from baseline in Apolipoprotein A-1 measured in grams per liter (g/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.
| g/L | Stayed at 5 mg: Tanner Stage 1 | Titrated to 10 mg: Tanner Stage 1 | Stayed at 10 mg: Tanner Stage 2+ | Titrated to 20 mg: Tanner Stage 2+ |
|---|---|---|---|---|
| Baseline | 1.42 ± 0.20 | 1.45 ± 0.20 | 1.29 ± 0.20 | 1.24 ± 0.15 |
| Week 2 | 0.01 ± 0.17 | -0.08 ± 0.23 | -0.09 ± 0.22 | -0.01 ± 0.15 |
| Week 4 | -0.09 ± 0.14 | -0.06 ± 0.13 | -0.06 ± 0.21 | 0.07 ± 0.29 |
| Week 6 | -0.14 ± 0.18 | -0.02 ± 0.11 | -0.07 ± 0.19 | -0.04 ± 0.23 |
| Week 8 | -0.03 ± 0.12 | -0.05 ± 0.13 | -0.04 ± 0.24 | -0.07 ± 0.21 |
Apolipoprotein A-1 (Apo A-1): percent (%) change from baseline by treatment over time = \[Apo A-1 at observation minus Apo A-1 at Week 0\] divided by Apo A-1 at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).
| percent change in Apo A-1 | Stayed at 5 mg: Tanner Stage 1 | Titrated to 10 mg: Tanner Stage 1 | Stayed at 10 mg: Tanner Stage 2+ | Titrated to 20 mg: Tanner Stage 2+ |
|---|---|---|---|---|
| Week 2 | 1.69 ± 11.21 | -5.24 ± 15.86 | -5.96 ± 16.76 | -0.53 ± 11.90 |
| Week 4 | -5.15 ± 8.20 | -3.30 ± 8.11 | -3.73 ± 16.43 | 7.54 ± 25.24 |
| Week 6 | -9.90 ± 14.01 | -0.97 ± 7.04 | -4.21 ± 14.81 | -2.82 ± 18.20 |
| Week 8 | -1.24 ± 8.49 | -3.37 ± 9.35 | -2.60 ± 20.22 | -4.82 ± 16.13 |
Change from baseline in Apolipoprotein B measured in grams per liter (g/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.
| g/L | Stayed at 5 mg: Tanner Stage 1 | Titrated to 10 mg: Tanner Stage 1 | Stayed at 10 mg: Tanner Stage 2+ | Titrated to 20 mg: Tanner Stage 2+ |
|---|---|---|---|---|
| Baseline | 1.09 ± 0.13 | 1.49 ± 0.24 | 1.26 ± 0.14 | 1.52 ± 0.18 |
| Week 2 | -0.23 ± 0.13 | -0.31 ± 0.19 | -0.39 ± 0.14 | -0.42 ± 0.16 |
| Week 4 | -0.33 ± 0.11 | -0.40 ± 0.13 | -0.44 ± 0.10 | -0.47 ± 0.22 |
| Week 6 | -0.27 ± 0.15 | -0.53 ± 0.17 | -0.42 ± 0.15 | -0.52 ± 0.18 |
| Week 8 | -0.30 ± 0.08 | -0.59 ± 0.15 | -0.41 ± 0.17 | -0.49 ± 0.30 |
Apolipoprotein B (Apo B): percent (%) change from baseline by treatment over time = \[Apo B at observation minus Apo B at Week 0\] divided by Apo B at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).
| percent change in Apo B | Stayed at 5 mg: Tanner Stage 1 | Titrated to 10 mg: Tanner Stage 1 | Stayed at 10 mg: Tanner Stage 2+ | Titrated to 20 mg: Tanner Stage 2+ |
|---|---|---|---|---|
| Week 2 | -21.92 ± 13.97 | -19.88 ± 10.96 | -30.81 ± 10.27 | -27.46 ± 8.89 |
| Week 4 | -29.89 ± 8.94 | -26.56 ± 5.33 | -34.69 ± 6.10 | -30.42 ± 11.86 |
| Week 6 | -24.58 ± 12.96 | -35.26 ± 6.85 | -33.26 ± 10.38 | -33.61 ± 9.59 |
| Week 8 | -27.39 ± 5.97 | -39.59 ± 5.83 | -31.94 ± 11.64 | -31.26 ± 18.57 |
Change from baseline in very low-density lipoprotein-cholesterol (VLDL-C) measured in millimoles per liter (mmol/L). Change from baseline = value at observation minus baseline value. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).
| mmol/L | Stayed at 5 mg: Tanner Stage 1 | Titrated to 10 mg: Tanner Stage 1 | Stayed at 10 mg: Tanner Stage 2+ | Titrated to 20 mg: Tanner Stage 2+ |
|---|---|---|---|---|
| Baseline | 0.54 ± 0.15 | 0.76 ± 0.30 | 0.65 ± 0.11 | 0.99 ± 0.31 |
| Week 2 | -0.22 ± 0.12 | -0.31 ± 0.38 | -0.12 ± 0.29 | -0.38 ± 0.33 |
| Week 4 | -0.18 ± 0.24 | -0.30 ± 0.27 | -0.14 ± 0.24 | -0.39 ± 0.35 |
| Week 6 | -0.01 ± 0.17 | -0.28 ± 0.32 | -0.20 ± 0.17 | -0.36 ± 0.28 |
| Week 8 | -0.13 ± 0.32 | -0.42 ± 0.28 | -0.35 ± 0.14 | -0.55 ± 0.32 |
Very low-density lipoprotein-cholesterol (VLDL-C): percent (%) change from baseline by treatment over time = \[VLDL-C at observation minus VLDL-C at Week 0\] divided by VLDL-C at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).
| percent change in VLDL-C | Stayed at 5 mg: Tanner Stage 1 | Titrated to 10 mg: Tanner Stage 1 | Stayed at 10 mg: Tanner Stage 2+ | Titrated to 20 mg: Tanner Stage 2+ |
|---|---|---|---|---|
| Week 2 | -42.20 ± 25.17 | -28.49 ± 43.50 | -14.50 ± 41.19 | -39.95 ± 37.24 |
| Week 4 | -30.66 ± 48.66 | -31.86 ± 37.62 | -21.10 ± 37.56 | -36.35 ± 28.79 |
| Week 6 | 4.10 ± 36.46 | -25.59 ± 44.90 | -29.20 ± 25.11 | -35.08 ± 25.06 |
| Week 8 | -12.31 ± 57.38 | -50.29 ± 21.44 | -53.61 ± 19.21 | -52.38 ± 29.34 |
Brachial artery flow-mediated dilatation (FMD) = (max minus baseline diameter divided by baseline diameter) x 100%. Standardized image acquisition: brachial artery images recorded for one minute at rest, blood pressure cuff inflated to 250 mm Hg for 5 minutes with brachial artery imaged continuously throughout cuff inflation, cuff released to produce reactive hyperaemia and the brachial artery imaged continuously for 3 minutes after release. Total duration of measurement approximately 25 minutes. Change from baseline = value at observation minus baseline value.
| FMD | Stayed at 5 mg: Tanner Stage 1 | Titrated to 10 mg: Tanner Stage 1 | Stayed at 10 mg: Tanner Stage 2+ | Titrated to 20 mg: Tanner Stage 2+ |
|---|---|---|---|---|
| Baseline | 4.34 ± 3.15 | 7.41 ± 3.30 | 5.05 ± 3.86 | 3.67 ± 2.51 |
| Week 8 | -0.16 ± 2.32 | -1.14 ± 1.47 | -0.32 ± 4.83 | 1.35 ± 2.73 |
Brachial Flow-Mediated Dilatation (FMD) = (max minus baseline diameter divided by baseline diameter) x 100%. .
| percent change in FMD | Stayed at 5 mg: Tanner Stage 1 | Titrated to 10 mg: Tanner Stage 1 | Stayed at 10 mg: Tanner Stage 2+ | Titrated to 20 mg: Tanner Stage 2+ |
|---|---|---|---|---|
| Percent Change From Baseline in Flow-Mediated Dilatation at Week 8 | -17.19 ± 23.67 | -20.77 ± 37.03 | -9.77 ± 63.20 | 1.49 ± 28.64 |
Parent-metabolite population PK model built using sparse blood samples from Tanner Stages 1 and 2+. Sampling times: Weeks 2 + 6: single sample between 4 -12 hours postdose; Weeks 4 + 8: predose, 1 + 2 hours postdose. Plasma samples analyzed for atorvastatin and active hydroxyacid metabolite (o-hydroxyatorvastatin) concentrations using validated, sensitive, specific high-performance liquid chromatography tandem mass spectrometric method. Vc/F value based on 70 kg body weight. Parameter estimation uncertainty (95% CI) by non-parametric bootstrap analysis. Data presented are result of model used.
| liters | Atorvastatin (5 mg, 10 mg, 20 mg): Tanner Stages 1 and 2+ |
|---|---|
| Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Apparent Volume of Distribution of the Central Compartment (Vc/F) | 1020 (209 to 2210) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Subjects (5 mg, 10 mg): Tanner Stage 1 | — | 0/15 (0%) | 9/15 (60%) |
| All Subjects (10 mg, 20 mg): Tanner Stage 2+ | — | 0/24 (0%) | 13/24 (54.2%) |
| Event | All Subjects (5 mg, 10 mg): Tanner Stage 1 | All Subjects (10 mg, 20 mg): Tanner Stage 2+ |
|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 3/15 | 0/24 |
| HeadacheNervous system disorders | 2/15 | 1/24 |
| NasopharyngitisInfections and infestations | 1/15 | 2/24 |
| Alanine aminotransferase increasedInvestigations | 0/15 | 2/24 |
| Abdominal painGastrointestinal disorders | 1/15 | 0/24 |
| NauseaGastrointestinal disorders | 1/15 | 0/24 |
| VomitingGastrointestinal disorders | 1/15 | 0/24 |
| BronchopneumoniaInfections and infestations | 1/15 | 0/24 |
| Gastritis viralInfections and infestations | 1/15 | 0/24 |
| GastroenteritisInfections and infestations | 1/15 | 1/24 |
| Age, Customized(participants) | Atorvastatin (5 mg, 10 mg): Tanner Stage 1 | Atorvastatin (10 mg, 20 mg): Tanner Stage 2+ | Total |
|---|---|---|---|
| 6-8 years | 7 | 0 | 7 |
| 9-10 years | 6 | 3 | 9 |
| 11-14 years | 2 | 14 | 16 |
| 15-17 years | 0 | 7 | 7 |
| Sex: Female, Male(Participants) | Atorvastatin (5 mg, 10 mg): Tanner Stage 1 | Atorvastatin (10 mg, 20 mg): Tanner Stage 2+ | Total |
|---|---|---|---|
| Female | 7 | 12 | 19 |
| Male | 8 | 12 | 20 |
The record gives a start of Dec 2008, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →